These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 21648211

  • 1. Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
    Prescrire Int; 2011 Apr; 20(115):95. PubMed ID: 21648211
    [Abstract] [Full Text] [Related]

  • 2. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [Abstract] [Full Text] [Related]

  • 3. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
    Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
    [Abstract] [Full Text] [Related]

  • 4. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.
    Hernandez RK, Farwell W, Cantor MD, Lawler EV.
    J Am Geriatr Soc; 2009 Nov; 57(11):1997-2003. PubMed ID: 19793162
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease.
    Starr JM.
    J Am Geriatr Soc; 2007 May; 55(5):800-1. PubMed ID: 17493206
    [No Abstract] [Full Text] [Related]

  • 10. Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.
    Wattmo C, Wallin AK, Londos E, Minthon L.
    Gerontologist; 2011 Feb; 51(1):17-27. PubMed ID: 20562471
    [Abstract] [Full Text] [Related]

  • 11. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB, Keohane DJ, Erwin WG, McRae T, Shah SN.
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
    Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R.
    Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
    Thompson S, Lanctôt KL, Herrmann N.
    Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
    [Abstract] [Full Text] [Related]

  • 20. Cardio-vascular safety of acetyl cholinesterase inhibitors in patients suffering from Alzheimer's disease; factors that predict poor tolerability.
    Kinnair D, Machili C, Prettyman R, Van Diepen E.
    Int J Geriatr Psychiatry; 2011 Mar; 26(3):328-9. PubMed ID: 21319335
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.